CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized, Controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of YL201 Versus Liposomal Irinotecan in Combination With 5-Fluorouracil/Leucovorin in Participants With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed Prior Gemcitabine-based Systemic Therapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07803783
Title field or adapter rule: {'original_value': 'A Randomized, Controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of YL201 Versus Liposomal Irinotecan in Combination With 5-Fluorouracil/Leucovorin in Participants With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed Prior Gemcitabine-based Systemic Therapy', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:26.456348+00:00
Published At: 2026-09-04T00:00:00+00:00
Record Updated At: 2026-09-04
Source Retrieved At: 2026-10-31T22:17:58.991924+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

protocolSection.conditionsModule.conditions: ["Metastatic Pancreatic Cancer", "Pancreatic Ductal Adenocarcinoma (PDAC)"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-09-04", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT07803783"
protocolSection.identificationModule.officialTitle: "A Randomized, Controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of YL201 Versus Liposomal Irinotecan in Combination With 5-Fluorouracil/Leucovorin in Participants With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed Prior Gemcitabine-based Systemic Therapy"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

{'armGroupLabels': ['Tambotatug pelitecan'], 'description': 'Drug: Tambotatug pelitecan\n\n2.0mg/kg (maximum 200mg)\n\nIntravenous infusion\n\nEvery 3 weeks\n\nTreatment will continue until disease progression or unacceptable toxicity.', 'name': 'Tambotatug pelitecan', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Chemotherapy'], 'description': 'Liposomal irinotecan\n\nIntravenous infusion\n\nEvery 2 weeks\n\nTreatment will continue until disease progression or unacceptable toxicity.', 'name': 'Liposomal irinotecan', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Chemotherapy'], 'description': '5 Fluorouracil\n\nIntravenous infusion\n\nEvery 2 weeks\n\nTreatment will continue until disease progression or unacceptable toxicity.', 'name': '5 Fluorouracil', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Chemotherapy'], 'description': 'Leucovorin\n\nIntravenous infusion\n\nEvery 2 weeks\n\nTreatment will continue until disease progression or unacceptable toxicity.', 'name': 'Leucovorin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.